Drug Database
Back to search

France· FR:67194402

GAVRETO 100 mg, gélule

A pralsetinib product containing pralsétinib, registered in France by BLUEPRINT MEDICINES (PAYS-BAS)). The same ATC class is registered in 8 of our 19 countries.

ATC L01EX23

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedGAVRETO 100 mg, géluleATCL01EX23REGISTER NO.FR:67194402PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about pralsétinibAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Pralsetinib is registered in 8 of 19 countries.

Countries holding a registration under ATC L01EX23 (pralsetinib), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 6 of them publish a price we can compare per daily dose
Search pralsetinib products by name

Pralsetinib · ATC L01EX23

8 / 19 countries

  • Belgiumprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
PRALSÉTINIB
Manufacturer
BLUEPRINT MEDICINES (PAYS-BAS))
Country
France (FR)
ATC code
L01EX23
ATC class
Pralsetinib
Defined daily dose
0.4 g, O
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400930241448
    1 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 60 gélule(s)

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

93 interactions on record for pralsetinib.

Graded by severity as the source publishes them — 16 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check pralsetinib against other medicinesHow interaction checks work

Pralsetinib · interactions on record

93 records

  • 16 severe
  • 77 moderate

Most severe, free to view

  • KetoconazoleH02CA03severe
  • ClarithromycinJ01FA09severe
  • KetoconazoleJ02AB02severe
  • Darunavir and cobicistatJ05AR14severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Pralsetinib in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All pralsetinib products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4c1841af-9946-4e42-a2cd-aee2996b1286
GET /v1/drugs/4c1841af-9946-4e42-a2cd-aee2996b1286?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "67194402",
  "date_amm": "2021-11-18",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/21/1555",
  "substance": "PRALSÉTINIB",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation abrogée",
  "statut_bdm": "Warning disponibilité",
  "forme_pharmaceutique": "gélule",
  "voies_administration": "orale",
  "etat_commercialisation": "Non commercialisée",
  "surveillance_renforcee": "Oui"
}
API referenceMCP serverPlans

See everything about pralsetinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console